Smac Peptidomimetic Intermediates for IAP Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Cancer cells often develop resistance to treatments by evading apoptosis through overexpression of Inhibitor of Apoptosis Proteins (IAPs), which neutralize Caspases, making it challenging to effectively induce programmed cell death and inhibit tumor growth.
Innovation Solution
Development of novel compounds, such as Compound A, that bind to the Smac binding pocket on IAPs, preventing their interaction with Caspases and promoting apoptosis in rapidly dividing cells, thereby inhibiting the Smac/IAP interaction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Inhibitor of Apoptosis Proteins (IAPs) are overexpressed to neutralize Caspases, then cancer cell survival is improved, but treatment effectiveness deteriorates
Solution Approach 1:
The patent introduces Smac mimetics as intermediary compounds that mediate between the apoptotic signaling pathway and IAP proteins. These mimetics bind to the BIR3 domain of IAPs, displacing endogenous Smac and preventing IAP-Caspase interaction, thereby restoring apoptosis without requiring direct modification of IAP overexpression levels
Solution Approach 2:
The patent employs peptide mimetics with modified amino acid sequences and structures (e.g., replacing native peptide bonds with isosteric linkages, incorporating non-natural amino acids) to change the biochemical parameters of Smac, creating compounds with enhanced stability and affinity for IAP binding while maintaining the ability to induce apoptosis
2Productivity
If Smac/IAP interaction is inhibited to promote apoptosis, then treatment effectiveness is improved, but selectivity against normal cells must be maintained
Solution Approach 1:
The patent designs Smac mimetics with localized modifications at specific binding interfaces (e.g., the IAP binding region) while maintaining other regions similar to endogenous Smac. This allows selective enhancement of IAP binding affinity and apoptosis induction in cancer cells while preserving normal cellular functions in healthy cells through differential expression patterns of IAPs and Smac
3Reliability
If novel Smac mimetics are developed to overcome IAP-mediated resistance, then treatment efficacy is improved, but compound complexity increases
Solution Approach 1:
The patent segments the Smac protein into functional domains, focusing specifically on the IAP binding region (IBR) for mimetic design. By concentrating modifications in this critical segment while simplifying other regions, the patent achieves high IAP binding affinity and apoptosis induction without excessive overall molecular complexity
Solution Approach 2:
The patent creates simplified copies of the endogenous Smac-IAP interaction interface using peptide mimetics that replicate the key binding features (hydrophobic interactions, hydrogen bonding networks) with reduced structural complexity. These mimetics copy only the essential elements needed for IAP binding and apoptosis induction, eliminating unnecessary complexity of the full Smac protein structure
Data Source
AI summary
The present invention is directed to compounds of the following formulae, which are intermediates in the synthesis of Smac peptidomimetics useful as IAP inhibitors: and